Skip to main content
SpringerLink
Log in

Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still’s disease

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

This study demonstrates whether serum β2-microglobulin (β2-MG) level can be an indicator of the status of systemic lupus erythematosus (SLE) and adult-onset Still’s disease (AOSD), and development of hemophagocytic syndrome (HPS) complication. Serum β2-MG level was compared between the active and inactive statuses of SLE and AOSD in hospitalized patients. Active status was defined as a state for which a therapy was introduced. Serum β2-MG level was also compared between patients with and without HPS complication. HPS was diagnosed on the basis of clinical and pathological findings. Laboratory markers of HPS including peripheral blood cell counts and levels of serum lactate dehydrogenase (LDH), serum ferritin, plasma fibrin/fibrinogen degradation product (FDP), and plasma D-dimer were examined to determine their correlations with serum β2-MG level. Sixteen SLE and seven AOSD patients (all females, aged 39.0 ± 16.4) were included. The serum β2-MG level was high in the active status of underlying diseases and decreased significantly after the therapy (3.5 ± 1.4 vs. 2.1 ± 0.8 mg/L, p < 0.001). Among patients with active status, the β2-MG level was higher in patients with HPS (two with SLE and three with AOSD) than in patients without HPS (4.9 ± 1.8 vs. 3.3 ± 1.4 mg/L, p < 0.05). Serum β2-MG level significantly correlated with the levels of serum LDH (r s = 0.42, p < 0.05), plasma FDP (r s = 0.58, p < 0.05), and plasma D-dimer (r s = 0.77, p < 0.01). Serum β2-MG level would be a useful indicator of disease activity and development of HPS complication in patients with SLE and AOSD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bethea M, Forman DT (1990) Beta 2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci 20(3):163–168

    PubMed  CAS  Google Scholar 

  2. Maury CP, Helve T, Sjoblom C (1982) Serum beta 2-microglobulin, sialic acid, and C-reactive protein in systemic lupus erythematosus. Rheumatol Int 2(4):145–149

    Article  PubMed  CAS  Google Scholar 

  3. Evrin PE, Strom T (1984) Beta 2-microglobulin and its binding activity in serum from patients with SLE. Ann Rheum Dis 43(2):267–274

    Article  PubMed  CAS  Google Scholar 

  4. Yeung CK, Wong KL, Wong WS, Chan KH (1986) Beta 2-microglobulin and systemic lupus erythematosus. J Rheumatol 13(6):1053–1058

    PubMed  CAS  Google Scholar 

  5. Font J, Coca A, Molina R, Ballesta A, Cardellach F, Ingelmo M, Balague A, Balcells A (1986) Serum beta 2-microglobulin as a marker of activity in systemic lupus erythematosus. Scand J Rheumatol 15(2):201–205

    Article  PubMed  CAS  Google Scholar 

  6. Kim HA, Jeon JY, Yoon JM, Suh CH (2010) Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci 339(4):337–340

    PubMed  Google Scholar 

  7. Castro J, Jimenez-Alonso J, Sabio JM, Rivera-Civico F, Martin-Armada M, Rodriguez MA, Jaimez L, Castillo MJ, Sanchez-Roman J (2003) Salivary and serum beta2-microglobulin and gamma-glutamyl-transferase in patients with primary Sjogren syndrome and Sjogren syndrome secondary to systemic lupus erythematosus. Clin Chim Acta 334(1–2):225–231

    PubMed  Google Scholar 

  8. Imashuku S (1997) Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol 66(2):135–151

    Article  PubMed  CAS  Google Scholar 

  9. Ramanan AV, Schneider R (2003) Macrophage activation syndrome–what's in a name! J Rheumatol 30(12):2513–2516

    PubMed  Google Scholar 

  10. Kumakura S, Ishikura H, Kondo M, Murakawa Y, Masuda J, Kobayashi S (2004) Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol 14(3):205–215

    Article  PubMed  Google Scholar 

  11. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725

    Article  PubMed  CAS  Google Scholar 

  12. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T et al (1992) Preliminary criteria for classification of adult Still's disease. J Rheumatol 19(3):424–430

    PubMed  CAS  Google Scholar 

  13. Tsuda H (1997) Hemophagocytic syndrome (HPS) in children and adults. Int J Hematol 65(3):215–226

    Article  PubMed  CAS  Google Scholar 

  14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992

    Article  PubMed  CAS  Google Scholar 

  15. Cooper EH, Plesner T (1980) Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol 8(4):323–334

    Article  PubMed  CAS  Google Scholar 

  16. Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G (2001) Reappraisal of serum beta2-microglobulin as marker of GFR. Ren Fail 23(3–4):419–429

    Article  PubMed  CAS  Google Scholar 

  17. Kaito K, Kobayashi M, Katayama T, Otsubo H, Ogasawara Y, Sekita T, Saeki A, Sakamoto M, Nishiwaki K, Masuoka H, Shimada T, Yoshida M, Hosoya T (1997) Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 59(4):247–253

    Article  PubMed  CAS  Google Scholar 

  18. Maruyama J, Inokuma S (2010) Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 37(5):967–973

    Article  PubMed  CAS  Google Scholar 

  19. Hibi S, Ikushima S, Fujiwara F, Hashida T, Tsunamoto K, Todo S, Imashuku S (1995) Serum and urine beta-2-microglobulin in hemophagocytic syndrome. Cancer 75(7):1700–1705

    Article  PubMed  CAS  Google Scholar 

  20. Onishi S, Ikenoya K, Matsumoto K, Kamata Y, Nagashima T, Kamimura T, Iwamoto M, Minota S (2008) Urinary beta2-microglobulin as a sensitive marker for haemophagocytic syndrome associated with collagen vascular diseases. Rheumatology (Oxford) 47(11):1730–1732

    Article  CAS  Google Scholar 

  21. Larroche C, Mouthon L (2004) Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 3(2):69–75

    Article  PubMed  CAS  Google Scholar 

  22. Osugi Y, Hara J, Tagawa S, Takai K, Hosoi G, Matsuda Y, Ohta H, Fujisaki H, Kobayashi M, Sakata N, Kawa-Ha K, Okada S, Tawa A (1997) Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89(11):4100–4103

    PubMed  CAS  Google Scholar 

  23. Takada H, Nomura A, Ohga S, Hara T (2001) Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk Lymphoma 42(1–2):21–28

    Article  PubMed  CAS  Google Scholar 

  24. Jordan MB, Hildeman D, Kappler J, Marrack P (2004) An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104(3):735–743

    Article  PubMed  CAS  Google Scholar 

  25. Kereveur A, McIlroy D, Samri A, Oksenhendler E, Clauvel JP, Autran B (1999) Up-regulation of adhesion and MHC molecules on splenic monocyte/macrophages in adult haemophagocytic syndrome. Br J Haematol 104(4):871–877

    Article  PubMed  CAS  Google Scholar 

  26. Barcy S, Wettendorff M, Leo O, Urbain J, Kruger M, Ceuppens JL, de Boer M (1995) FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. Int Immunol 7(2):179–189

    Article  PubMed  CAS  Google Scholar 

  27. Arlet JB, Le TH, Marinho A, Amoura Z, Wechsler B, Papo T, Piette JC (2006) Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis 65(12):1596–1601

    Article  PubMed  Google Scholar 

  28. Wong KF, Hui PK, Chan JK, Chan YW, Ha SY (1991) The acute lupus hemophagocytic syndrome. Ann Intern Med 114(5):387–390

    Article  PubMed  CAS  Google Scholar 

  29. Lambotte O, Khellaf M, Harmouche H, Bader-Meunier B, Manceron V, Goujard C, Amoura Z, Godeau B, Piette JC, Delfraissy JF (2006) Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine (Baltimore) 85(3):169–182

    Article  Google Scholar 

  30. Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, Atsumi T, Koike T (2008) Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) 47(11):1686–1691

    Article  CAS  Google Scholar 

  31. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131

    Article  PubMed  Google Scholar 

  32. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, Viola S, Martini A (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 146(5):598–604

    Article  PubMed  Google Scholar 

  33. Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, Cron RQ, Ravelli A (2011) An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 38(4):764–768

    Article  PubMed  Google Scholar 

  34. Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34(5):1133–1138

    PubMed  Google Scholar 

  35. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA (2007) The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56(3):965–971

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Department of Allergy and Rheumatic Diseases, Japanese Red Cross Medical Center, Tokyo, Japan

    Kuninobu Wakabayashi, Shigeko Inokuma, Erika Matsubara, Kae Onishi, Hiromitsu Asashima, Shinichiro Nakachi & Kiyofumi Hagiwara

  2. Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan

    Kuninobu Wakabayashi

Authors
  1. Kuninobu Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeko Inokuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erika Matsubara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kae Onishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiromitsu Asashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinichiro Nakachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kiyofumi Hagiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kuninobu Wakabayashi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wakabayashi, K., Inokuma, S., Matsubara, E. et al. Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still’s disease. Clin Rheumatol 32, 999–1005 (2013). https://doi.org/10.1007/s10067-013-2220-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-013-2220-8

Keywords

Search

Navigation